Perspectives in clinical gastroenterology and hepatologyBiosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation
Keywords
Abbreviations used in this paper
Cited by (0)
Conflicts of interest The authors disclose the following: Shomron Ben-Horin has received consultancy and/or advisory board fees from Schering-Plough, AbbVie, CELLTRION, Janssen, and Takeda and has received research support from CELLTRION and AbbVie. Niels Vande Casteele is a Postdoctoral Fellow of the Research Foundation - Flanders (FWO), Belgium (grant number 1260714N) and has received consultancy fees from MSD, Janssen Biologics BV, UCB, Pfizer, and Takeda and lecture fees from AbbVie. Stefan Schreiber has served on advisory boards for AbbVie, Biogen, CELLTRION, Hospira, Merck, Mundipharma, Takeda, and UCB and has given paid lectures for AbbVie, Hospira, Merck, Mundipharma, and Takeda. Peter Laszlo Lakatos has served as a speaker and/or advisory board member for AbbVie, CELLTRION, EGIS, Falk Pharma GmbH, Ferring, Genentech, Kyowa Hakko Kirin Pharma, Mitsubishi Tanabe Pharma Corporation, MSD, Otsuka, Pharmacosmos, Pfizer, Roche, and Takeda and has received unrestricted research grants from AbbVie, MSD, and Pfizer/Hospira.
Funding Medical writing assistance was provided by Alice Wareham, PhD at Aspire Scientific Limited (Bollington, United Kingdom) and was funded by CELLTRION Healthcare Co, Ltd (Incheon, Republic of Korea).